Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04925193 · OUTCOME

Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma · Source last updated 2026-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study drug through 30 days after last dose of protocol required therapies

What was measured

Occurrence, nature, and severity of adverse events

Analysis population: Outcome measure data table indicates number of patients who experienced adverse events on each arm. Refer to adverse events table for detailed information.

Groups in this outcome

Arm 1

Selinexor 60 mg PO days 1, 8, 15 Pomalidomide 4 mg PO on days 1-21 Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 28 day treatment cycles

Arm 3

Selinexor 80 mg PO days 1, 8, 15 Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 28 day treatment cycle

Arm 2

Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 13
Arm 36
Arm 29

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 13Not reportedNot reportedNot reportedNot reported
Arm 36Not reportedNot reportedNot reportedNot reported
Arm 29Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      6
    3. group Id
      OG002
      value
      9
    units
    Participants
description
Occurrence, nature, and severity of adverse events
groups
  1. description
    Selinexor 60 mg PO days 1, 8, 15 Pomalidomide 4 mg PO on days 1-21 Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 28 day treatment cycles
    id
    OG000
    title
    Arm 1
  2. description
    Selinexor 80 mg PO days 1, 8, 15 Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 28 day treatment cycle
    id
    OG001
    title
    Arm 3
  3. description
    Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle
    id
    OG002
    title
    Arm 2
param Type
COUNT_OF_PARTICIPANTS
population Description
Outcome measure data table indicates number of patients who experienced adverse events on each arm. Refer to adverse events table for detailed information.
reporting Status
POSTED
time Frame
From first dose of study drug through 30 days after last dose of protocol required therapies
title
Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice